Empress Therapeutics
Dan Liang is a skilled computational biologist currently serving as a Senior Scientist I at Empress Therapeutics since February 2025. Prior to this role, Dan worked at Bexorg, Inc. as a Research Scientist from September 2022 to February 2025. Dan also held postdoctoral positions at Yale University from May 2021 to June 2023, during which time valuable research contributions were made. Dan earned a degree from the University of North Carolina at Chapel Hill, completing studies in May 2021.
This person is not in any offices
Empress Therapeutics
Founded by Flagship Pioneering, Empress re-imagines the process of small molecule drug discovery. Our bioplatform harnesses the power of evolution, human molecular and genetic data, and artificial intelligence to focus on endogenous sources of inherently drug-like small molecules as a uniquely qualified source of potential drugs. Our mission is to generate transformative drug candidates that get to the clinic faster and cheaper, with a higher probability of success.